doi:10.3969/j.issn.1004-583X.2021.01.015

Abstract

CLC Number:

R442.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.01.015

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I1/70

References 35

[1]	徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南(2017, 北京)[J]. 中华胃肠内镜电子杂志, 2018,5(1):1-17.
[2]	Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006,4(11):1385-1394. doi: 10.1016/j.cgh.2006.08.007 URL
[3]	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018,69(2):406-460. doi: 10.1016/j.jhep.2018.03.024 URL
[4]	丁惠国. 从《肝硬化腹水及相关并发症的诊疗指南》探讨肝硬化顽固性腹水诊治"路线图"[J]. 临床肝胆病杂志, 2018,34(1):31-34.
[5]	Josiassen RC, Curtis J, Filmyer DM, et al. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders[J]. Expert Opin Pharmacother, 2010,11(4):637-648. doi: 10.1517/14656561003610656 pmid: 20163274
[6]	Sakaida I, Nakajima K, Okita K, et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan[J]. J Gastroenterol, 2015,50(10):1047-1053. doi: 10.1007/s00535-015-1052-5 URL
[7]	Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites[J]. Hepatol Res, 2019,49(7):765-777.
[8]	Wang S, Zhang X, Han T, et al. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia[J]. BMC Gastroenterol, 2018,18(1):137. doi: 10.1186/s12876-018-0857-0 URL
[9]	邢枫, 李爽, 张建军, 等. 特利加压素对顽固性肝硬化腹水的治疗作用与效应特点观察[J]. 中华肝脏病杂志, 2019,27(12):982-988.
[10]	Wong F, Pappas SC, Boyer TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017,15(2):266-272. doi: 10.1016/j.cgh.2016.07.016 URL
[11]	Singh V, Dhungana SP, Singh B, et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study[J]. J Hepatol, 2012,56(2):348-354. doi: 10.1016/j.jhep.2011.04.027 URL
[12]	Guo TT, Yang Y, Song Y, et al. Effects of midodrine in patients with ascites due to cirrhosis: systematic review and meta-analysis[J]. J Dig Dis, 2016,17(1):11-19. doi: 10.1111/1751-2980.12304 URL
[13]	Lin CH, Shih FY, Ma MH, et al. Should bleeding tendency deter abdominal paracentesis?[J]. Dig Liver Dis, 2005,37(12):946-951. doi: 10.1016/j.dld.2005.07.009 URL
[14]	Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study[J]. Dig Liver Dis, 2011,43(11):881-886. doi: 10.1016/j.dld.2011.06.001 pmid: 21741331
[15]	Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites[J]. Liver Int, 2019,39(1):98-105. doi: 10.1111/liv.13968 pmid: WOS:000454415500012
[16]	Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites[J]. Hepatology, 2004,40(3):629-635. doi: 10.1002/(ISSN)1527-3350 URL
[17]	Rossle M. TIPS: 25 years later[J]. J Hepatol, 2013,59(5):1081-1093. doi: 10.1016/j.jhep.2013.06.014 URL
[18]	中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南[J]. 中华肝脏病杂志, 2019,27(8):582-593.
[19]	Bucsics T, Hoffman S, Grunberger J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis[J]. Liver Int, 2018,38(6):1036-1044. doi: 10.1111/liv.2018.38.issue-6 URL
[20]	林志鹏, 赵剑波, 陈斯良. 采用Viatorr覆膜支架建立经颈静脉肝内门体静脉分流术的中期疗效分析[J]. 中华肝脏病杂志, 2019,27(6):440-444.
[21]	蒋明明, 徐浩, 张庆桥, 等. 经颈静脉肝内门体分流术在门静脉高压并发顽固性腹水及静脉曲张出血患者个体化治疗中的初步应用[J]. 中华医学杂志, 2019,99(47):3737-3740.
[22]	Bureau C, Adebayo D, Chalret DRM, et al. Alfapump(R) system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study[J]. J Hepatol, 2017,67(5):940-949. doi: 10.1016/j.jhep.2017.06.010 URL
[23]	Wong F, Bendel E, Sniderman K, et al. Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump[J]. Liver Transpl, 2020,26(5):651-661. doi: 10.1002/lt.v26.5 URL
[24]	Hanada R, Yokomichi N, Kato C, et al. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study[J]. Support Care Cancer, 2018,26(5):1489-1497. doi: 10.1007/s00520-017-3980-5 pmid: 29168037
[25]	Yoshizawa M, Nakatsuji Y. Improvement of major problems in the cell-free and concentrated ascites reinfusion therapy system horizontal line constructing of cell-free and concentrated ascites reinfusion therapy system using external pressure for filtration[J]. Ther Apher Dial, 2019,23(3):233-236. doi: 10.1111/tap.2019.23.issue-3 URL
[26]	陈照林, 董静, 宋海燕, 等. 特利加压素联合腹水浓缩回输术治疗肝硬化并发顽固性腹水患者临床研究[J]. 实用肝脏病杂志, 2020,23(4):556-559.
[27]	王新亭, 张传雷, 陈晓琦, 等. 腹水超滤浓缩腹腔回输联合周期性白蛋白输注治疗顽固性腹水的效果观察[J]. 中国临床新医学, 2018,11(6):554-558.
[28]	Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J]. Clin Gastroenterol Hepatol, 2012,10(7):815-818. doi: 10.1016/j.cgh.2012.02.025 URL
[29]	Lv XY, Ding HG, Zheng JF, et al. Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study[J]. World J Gastroenterol, 2020,26(2):199-218. doi: 10.3748/wjg.v26.i2.199 URL
[30]	Singh V, Singh A, Singh B, et al. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study[J]. Am J Gastroenterol, 2013,108(4):560-567. doi: 10.1038/ajg.2013.9 URL
[31]	Aday AW, Mayo MJ, Elliott A, et al. The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites[J]. Am J Med Sci, 2016,351(2):169-176. doi: 10.1016/j.amjms.2015.11.018 URL
[32]	Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010,52(3):1017-1022. doi: 10.1002/hep.23775 URL
[33]	Krag A, Wiest R, Albillos A, et al. The window hypojournal: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease[J]. Gut, 2012,61(7):967-969. doi: 10.1136/gutjnl-2011-301348 URL
[34]	Homler H. Beta-blocker use in refractory ascites[J]. Mayo Clin Proc, 2019,94(11):2364.
[35]	王宏彬, 汪小平. 小剂量奥曲肽用于肝硬化顽固性腹水疗效观察[J]. 山东医药, 2011,51(19):59-60.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 35

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ma Xiaojuan, Zhang Xu, Jiang Yong. Etiological analysis in 111 patients with ascites [J]. Clinical Focus, 2016, 31(2): 211-213.
[2]	. Hyperthermic intraperitoneal chemotherapy on tumor markers CA125 and CA19-9 level in patients with malignant ascites [J]. Clinical Focus, 2015, 30(10): 1156-1159.
[3]	. [J]. Clinical Focus, 2012, 27(6): 488-0.
[4]	. [J]. CLINICAL FOCUS, 2011, 26(9): 794-795.
[5]	. [J]. CLINICAL FOCUS, 2009, 24(6): 513-515.
[6]	. [J]. CLINICAL FOCUS, 2008, 23(18): 1356-1357.
[7]	. [J]. CLINICAL FOCUS, 2007, 22(18): 1355-1355.
[8]	. [J]. CLINICAL FOCUS, 2006, 21(11): 813-814.
[9]	. [J]. CLINICAL FOCUS, 2006, 21(2): 109-110.
[10]	. [J]. CLINICAL FOCUS, 2005, 20(20): 0-0.
[11]	. [J]. CLINICAL FOCUS, 2005, 20(12): 689-690.
[12]	. [J]. CLINICAL FOCUS, 2003, 18(22): 1288-1288.
[13]	. [J]. CLINICAL FOCUS, 2003, 18(12): 707-708.
[14]	. [J]. CLINICAL FOCUS, 2002, 17(22): 1362-1363.
[15]	. [J]. CLINICAL FOCUS, 2002, 17(22): 1363-1365.